Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

London

Diversity in immunology

The "Diversity in Immunology" conference for this year is set to celebrate both the immune system's intrinsic diversity, which is vital for providing adequate immunity [...]

Go to Top